Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 11:55AM ET
4.07
Dollar change
+0.01
Percentage change
0.25
%
Index- P/E- EPS (ttm)-72.07 Insider Own0.80% Shs Outstand0.53M Perf Week-9.15%
Market Cap2.16M Forward P/E- EPS next Y-10.50 Insider Trans0.00% Shs Float0.53M Perf Month-40.59%
Income-17.41M PEG- EPS next Q-11.59 Inst Own8.30% Short Float5.44% Perf Quarter-50.93%
Sales0.00M P/S- EPS this Y-1966.44% Inst Trans- Short Ratio0.30 Perf Half Y-70.77%
Book/sh27.62 P/B0.15 EPS next Y66.67% ROA-63.16% Short Interest0.03M Perf Year-95.11%
Cash/sh31.89 P/C0.13 EPS next 5Y- ROE-123.54% 52W Range3.81 - 92.62 Perf YTD-48.90%
Dividend Est.- P/FCF- EPS past 5Y46.80% ROI-98.83% 52W High-95.61% Beta4.87
Dividend TTM- Quick Ratio2.64 Sales past 5Y-3.68% Gross Margin71.07% 52W Low6.82% ATR (14)0.75
Dividend Ex-Date- Current Ratio2.64 EPS Y/Y TTM-191.12% Oper. Margin0.00% RSI (14)35.99 Volatility9.99% 18.21%
Employees40 Debt/Eq0.44 Sales Y/Y TTM-100.00% Profit Margin- Recom1.00 Target Price10.50
Option/ShortNo / No LT Debt/Eq0.44 EPS Q/Q57.76% Payout0.00% Rel Volume2.66 Prev Close4.06
Sales Surprise- EPS Surprise39.75% Sales Q/Q- EarningsMar 06 BMO Avg Volume96.35K Price4.07
SMA20-22.45% SMA50-33.48% SMA200-79.16% Trades Volume103,474 Change0.25%
Date Action Analyst Rating Change Price Target Change
Nov-05-18Initiated Ladenburg Thalmann Buy
Oct-05-17Resumed Piper Jaffray Overweight $6
Mar-18-24 06:00AM
Mar-07-24 08:55AM
Mar-05-24 01:51PM
08:05AM
Mar-04-24 09:00AM
08:05AM Loading…
Nov-14-23 08:05AM
Nov-01-23 07:45AM
Aug-10-23 08:05AM
Aug-06-23 07:14AM
Aug-04-23 06:40PM
Aug-01-23 10:15PM
Jul-30-23 02:17PM
Jul-18-23 08:05AM
May-11-23 08:05AM
Apr-01-23 08:51AM
07:45AM Loading…
Mar-30-23 07:45AM
07:30AM
Mar-29-23 10:13AM
Mar-03-23 06:57PM
Feb-13-23 08:05AM
Jan-09-23 08:05AM
Dec-12-22 09:54AM
07:35AM
Nov-10-22 08:05AM
Nov-09-22 08:05AM
Nov-03-22 09:06AM
Sep-19-22 08:45AM
Aug-11-22 08:05AM
Jun-09-22 08:05AM
May-12-22 08:05AM
08:05AM Loading…
Apr-12-22 08:05AM
Mar-29-22 08:05AM
Mar-24-22 08:05AM
Feb-09-22 08:05AM
Jan-21-22 08:05AM
Dec-15-21 08:05AM
Dec-10-21 05:38PM
Nov-23-21 08:05AM
07:59AM
Nov-15-21 08:05AM
Nov-12-21 08:05AM
Nov-11-21 04:45PM
08:30AM
Nov-02-21 09:00AM
Oct-27-21 08:05AM
Oct-26-21 08:05AM
Sep-28-21 08:05AM
Aug-17-21 08:05AM
Aug-12-21 08:05AM
Jul-16-21 08:05AM
Jun-29-21 08:05AM
May-27-21 09:00AM
May-26-21 09:32AM
09:00AM
May-17-21 06:00AM
May-11-21 09:00AM
Apr-09-21 09:00AM
Mar-31-21 08:00AM
Feb-09-21 07:30PM
Jan-11-21 08:00AM
Jan-06-21 12:00PM
Dec-19-20 01:45PM
Dec-02-20 08:00AM
Nov-20-20 07:37AM
Nov-19-20 04:15PM
Nov-16-20 08:00AM
Nov-10-20 08:40AM
Nov-09-20 09:00AM
06:00AM
Nov-08-20 11:15PM
Nov-03-20 09:00AM
Sep-01-20 09:00AM
Aug-14-20 09:00AM
Aug-06-20 09:00AM
Jul-21-20 09:00AM
Jun-30-20 12:00PM
11:30AM
Jun-29-20 09:00AM
Jun-25-20 09:00AM
Jun-10-20 09:00AM
May-13-20 09:00AM
Apr-14-20 09:00AM
Mar-25-20 09:00AM
Mar-16-20 09:00AM
Feb-28-20 09:05AM
08:59AM
Jan-30-20 09:00AM
Jan-13-20 08:00AM
Dec-19-19 03:50PM
Dec-06-19 09:00AM
Nov-12-19 09:00AM
Nov-08-19 09:00AM
Nov-07-19 09:00AM
Oct-04-19 07:32AM
Oct-03-19 04:02PM
Sep-19-19 09:00AM
Aug-09-19 09:00AM
Aug-07-19 09:02AM
Jul-25-19 04:32PM
Jun-25-19 09:00AM
Aptevo Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on developing novel immunotherapies for the treatment of cancer. Its pipeline APVO436, ALG.APV-527 and APVO603 were developed based on the ADAPTIR modular protein platform technology and APVO442 was developed based on the new ADAPTIR-FLE platform technology. The ADAPTIR and ADAPTIR-FLEX are capable of generating differentiated bispecific and multi-specific antibodies with potentially unique mechanisms of action for the treatment of different types of cancer. The company was founded in February 2016 and is headquartered in Seattle, WA.